Octagon Capital Advisors LP

NEW YORK, NY · CIK 1839435 · 13F filing filed 2026-08-14

SEC-registered investment adviser since 2020 · limited partnership

Assets managed$1.2bn
Staff10 · 7 in investment roles
Main clients (by assets)Private funds 100%
Private funds4 (1 hedge) · $1.2bn gross assets
Websiteoctagoninvestments.com
Form ADV · 2026-03-20SEC adviser record

Legal entityOCTAGON CAPITAL ADVISORS LP (US)

$1.1bn reported value +20.6% vs Q1 2026

26positions

80.2%in top 10

4 new 4 added 6 reduced 7 sold out vs Q1 2026

Options: 1 call positions ($23.0m notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#	Security	Ticker	Shares	Value	% of portfolio	Change	Shares change
1	DIANTHUS THERAPEUTICS INC COM DNTH	DNTH	1,841,667	$179.5m16.48%	16.48%	Reduced -105.0k	-105,000 -5.4%
2	DEFINIUM THERAPEUTICS INC COM SHS DFTX	DFTX	2,950,000	$138.8m12.74%	12.74%	Added +510.0k	+510,000 20.9%
3	ABIVAX SA SPONSORED ADS ABVX	ABVX	993,000	$132.3m12.15%	12.15%	Added +316.0k	+316,000 46.7%
4	COGENT BIOSCIENCES INC COM COGT	COGT	2,350,000	$90.9m8.35%	8.35%	Unchanged
5	ALUMIS INC COM ALMS	ALMS	2,830,700	$79.7m7.31%	7.31%	Unchanged
6	ARRIVENT BIOPHARMA INC COM AVBP	AVBP	1,971,054	$68.5m6.28%	6.28%	Unchanged
7	TAYSHA GENE THERAPIES INC COM SHS TSHA	TSHA	9,693,244	$66.0m6.06%	6.06%	Added +833.3k	+833,333 9.4%
8	BIOAGE LABS INC COM BIOA	BIOA	1,748,000	$42.8m3.93%	3.93%	Unchanged
9	MIRUM PHARMACEUTICALS INC COM MIRM	MIRM	338,900	$39.7m3.64%	3.64%	Unchanged
10	KYMERA THERAPEUTICS INC COM KYMR	KYMR	310,000	$35.5m3.26%	3.26%	Reduced -115.0k	-115,000 -27.1%
11	AKTIS ONCOLOGY INC COM AKTS	AKTS	960,847	$31.0m2.84%	2.84%	Unchanged
12	XENON PHARMACEUTICALS INC COM XENE	XENE	490,000	$29.6m2.71%	2.71%	Unchanged
13	PALISADE BIO INC COM PALI	PALI	10,276,317	$21.5m1.97%	1.97%	Unchanged
14	OCULAR THERAPEUTIX INC COM OCUL	OCUL	2,075,000	$20.4m1.87%	1.87%	Reduced -1.1m	-1,091,600 -34.5%
15	DISC MEDICINE INC COM IRON	IRON	270,000	$19.7m1.81%	1.81%	Unchanged
16	SUMMIT THERAPEUTICS INC COM SMMT	SMMT	1,250,000	$18.2m1.67%	1.67%	New
17	PHARVARIS N V COM PHVS	PHVS	456,721	$15.8m1.45%	1.45%	Added +291.7k	+291,721 176.8%
18	ADLAI NORTYE LTD SPONSORED ADS ANL	ANL	934,716	$10.7m0.99%	0.99%	New
19	PRECISION BIOSCIENCES INC COM NEW DTIL	DTIL	1,350,000	$10.6m0.97%	0.97%	Reduced -886.7k	-886,732 -39.6%
20	DBV TECHNOLOGIES S A SPONSORED ADS DBVT	DBVT	574,200	$9.4m0.86%	0.86%	Unchanged
21	FAETH THERAPEUTICS INC COM NEW FTH	FTH	361,010	$9.0m0.83%	0.83%	New
22	GYRE THERAPEUTICS INC COM GYRE	GYRE	954,416	$6.3m0.58%	0.58%	New
23	TREVI THERAPEUTICS INC COM TRVI	TRVI	315,000	$5.9m0.54%	0.54%	Reduced -1.2m	-1,170,000 -78.8%
24	UNICYCIVE THERAPEUTICS INC COM NEW UNCY	UNCY	1,000,000	$4.7m0.43%	0.43%	Unchanged
25	CONTEXT THERAPEUTICS INC COM CNTX	CNTX	3,050,000	$1.7m0.16%	0.16%	Reduced -2.2m	-2,200,000 -41.9%
26	GOSSAMER BIO INC COM GOSS	GOSS	7,750,000	$1.3m0.12%	0.12%	Unchanged

Sold out since Q1 2026

Security	Ticker	Shares held before	Value then
CENTESSA PHARMACEUTICALS PLC		750,000	$29.8m750.0k shares
KALVISTA PHARMACEUTICALS INC KALV	KALV	1,450,000	$29.2m1.4m shares
TERNS PHARMACEUTICALS INC		530,000	$27.9m530.0k shares
BRIDGEBIO ONCOLOGY THERAPEUT BBOT	BBOT	719,000	$6.4m719.0k shares
LEXEO THERAPEUTICS INC LXEO	LXEO	1,100,000	$6.3m1.1m shares
PERSPECTIVE THERAPEUTICS INC CATX	CATX	791,555	$3.3m791.6k shares
EVOMMUNE INC EVMN	EVMN	143,472	$3.3m143.5k shares

Options (notional value)

Underlying	Ticker	Type	Shares controlled	Notional	Change
ERASCA INC ERAS · Call	ERAS	Call	1,255,000	$23.0m1.3m shares	New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

Company	Ticker	Stake	Change	Schedule	Last filed
PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-02-10	DTIL	10.0%≈ $18.3m	new	13G	2026-02-10
PALISADE BIO INC PALI · 13G · filed 2026-02-10	PALI	6.4%≈ $20.0m	new	13G	2026-02-10